University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Phase II Study of Bevacizumab Alone or in Combination with TRC105 for Advanced Renal Cell Cancer

Participants in this research study have kidney cancer that has spread to other places in their bodies, and has grown worse despite treatment received.

The purpose of this research study is to find out whether adding an investigational new drug, TRC105, to bevacizumab, a drug which has been approved by the FDA for the treatment of kidney cancer, will result in longer cancer control than bevacizumab alone.

Approximately 5 people will take part in this study conducted by investigators at the University of Iowa. About 88 people will take part in this study at other institutions.

Start Date
May 22, 2013
End Date
December 1, 2015
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Daniel Vaena, MD
Contact Info

Pamela Zehr, 319-353-8914

bevacizumab ; cancer ; IRB#201304704 ; kidney ; TRC105 ; vaena ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.